Format
Items per page
Sort by

Send to:

Choose Destination

Links from PubMed

Items: 1 to 20 of 102

1.

Enhanced immunogenicity of a bivalent nicotine vaccine.

Keyler DE, Roiko SA, Earley CA, Murtaugh MP, Pentel PR.

Int Immunopharmacol. 2008 Nov;8(11):1589-94. doi: 10.1016/j.intimp.2008.07.001. Epub 2008 Jul 24.

2.

Immunogenicity of individual vaccine components in a bivalent nicotine vaccine differ according to vaccine formulation and administration conditions.

Cornish KE, de Villiers SH, Pravetoni M, Pentel PR.

PLoS One. 2013 Dec 2;8(12):e82557. doi: 10.1371/journal.pone.0082557. eCollection 2013.

3.

Structurally distinct nicotine immunogens elicit antibodies with non-overlapping specificities.

Pravetoni M, Keyler DE, Pidaparthi RR, Carroll FI, Runyon SP, Murtaugh MP, Earley CA, Pentel PR.

Biochem Pharmacol. 2012 Feb 15;83(4):543-50. doi: 10.1016/j.bcp.2011.11.004. Epub 2011 Nov 15.

4.

Combined active and passive immunization against nicotine: minimizing monoclonal antibody requirements using a target antibody concentration strategy.

Cornish KE, Harris AC, LeSage MG, Keyler DE, Burroughs D, Earley C, Pentel PR.

Int Immunopharmacol. 2011 Nov;11(11):1809-15. doi: 10.1016/j.intimp.2011.07.009. Epub 2011 Jul 28.

5.

Increased efficacy of a trivalent nicotine vaccine compared to a dose-matched monovalent vaccine when formulated with alum.

de Villiers SH, Cornish KE, Troska AJ, Pravetoni M, Pentel PR.

Vaccine. 2013 Dec 16;31(52):6185-93. doi: 10.1016/j.vaccine.2013.10.051. Epub 2013 Oct 29.

6.

New directions in nicotine vaccine design and use.

Pentel PR, LeSage MG.

Adv Pharmacol. 2014;69:553-80. doi: 10.1016/B978-0-12-420118-7.00014-7. Review.

7.

Active immunization alters the plasma nicotine concentration in rats.

Hieda Y, Keyler DE, Vandevoort JT, Kane JK, Ross CA, Raphael DE, Niedbalas RS, Pentel PR.

J Pharmacol Exp Ther. 1997 Dec;283(3):1076-81.

8.

Co-administration of morphine and oxycodone vaccines reduces the distribution of 6-monoacetylmorphine and oxycodone to brain in rats.

Pravetoni M, Raleigh MD, Le Naour M, Tucker AM, Harmon TM, Jones JM, Birnbaum AK, Portoghese PS, Pentel PR.

Vaccine. 2012 Jun 29;30(31):4617-24. doi: 10.1016/j.vaccine.2012.04.101. Epub 2012 May 11.

9.

Combined active and passive immunization enhances the efficacy of immunotherapy against nicotine in rats.

Roiko SA, Harris AC, Keyler DE, Lesage MG, Zhang Y, Pentel PR.

J Pharmacol Exp Ther. 2008 Jun;325(3):985-93. doi: 10.1124/jpet.107.135111. Epub 2008 Feb 27.

10.

Probing the protective effects of a conformationally constrained nicotine vaccine.

Moreno AY, Azar MR, Koob GF, Janda KD.

Vaccine. 2012 Oct 19;30(47):6665-70. doi: 10.1016/j.vaccine.2012.08.064. Epub 2012 Sep 7.

PMID:
22963803
11.

The immunogenicity and safety of a nicotine vaccine in smokers and nonsmokers: results of a randomized, placebo-controlled phase 1/2 trial.

Wagena EJ, de Vos A, Horwith G, van Schayck CP.

Nicotine Tob Res. 2008 Jan;10(1):213-8. doi: 10.1080/14622200701704921.

PMID:
18188762
12.

Thomsen-Friedenreich (TF) antigen as a target for prostate cancer vaccine: clinical trial results with TF cluster (c)-KLH plus QS21 conjugate vaccine in patients with biochemically relapsed prostate cancer.

Slovin SF, Ragupathi G, Musselli C, Fernandez C, Diani M, Verbel D, Danishefsky S, Livingston P, Scher HI.

Cancer Immunol Immunother. 2005 Jul;54(7):694-702. Epub 2005 Feb 22.

PMID:
15726361
13.

Comparison of antibody titers after immunization with monovalent or tetravalent KLH conjugate vaccines.

Ragupathi G, Cappello S, Yi SS, Canter D, Spassova M, Bornmann WG, Danishefsky SJ, Livingston PO.

Vaccine. 2002 Jan 15;20(7-8):1030-8.

PMID:
11803062
14.

An oxycodone conjugate vaccine elicits drug-specific antibodies that reduce oxycodone distribution to brain and hot-plate analgesia.

Pravetoni M, Le Naour M, Harmon TM, Tucker AM, Portoghese PS, Pentel PR.

J Pharmacol Exp Ther. 2012 Apr;341(1):225-32. doi: 10.1124/jpet.111.189506. Epub 2012 Jan 18.

15.

Immunogenicity and smoking-cessation outcomes for a novel nicotine immunotherapeutic.

Hatsukami DK, Jorenby DE, Gonzales D, Rigotti NA, Glover ED, Oncken CA, Tashkin DP, Reus VI, Akhavain RC, Fahim RE, Kessler PD, Niknian M, Kalnik MW, Rennard SI.

Clin Pharmacol Ther. 2011 Mar;89(3):392-9. doi: 10.1038/clpt.2010.317. Epub 2011 Jan 26.

16.

Selective effects of a morphine conjugate vaccine on heroin and metabolite distribution and heroin-induced behaviors in rats.

Raleigh MD, Pravetoni M, Harris AC, Birnbaum AK, Pentel PR.

J Pharmacol Exp Ther. 2013 Feb;344(2):397-406. doi: 10.1124/jpet.112.201194. Epub 2012 Dec 7.

17.

A preclinical study comparing approaches for augmenting the immunogenicity of a heptavalent KLH-conjugate vaccine against epithelial cancers.

Ragupathi G, Koide F, Sathyan N, Kagan E, Spassova M, Bornmann W, Gregor P, Reis CA, Clausen H, Danishefsky SJ, Livingston PO.

Cancer Immunol Immunother. 2003 Oct;52(10):608-16. Epub 2003 Jun 17.

PMID:
12811527
18.

Tissue-dependent effects of immunization with a nicotine conjugate vaccine on the distribution of nicotine in rats.

Satoskar SD, Keyler DE, LeSage MG, Raphael DE, Ross CA, Pentel PR.

Int Immunopharmacol. 2003 Jul;3(7):957-70.

PMID:
12810353
19.
20.

Consistent antibody response against ganglioside GD2 induced in patients with melanoma by a GD2 lactone-keyhole limpet hemocyanin conjugate vaccine plus immunological adjuvant QS-21.

Ragupathi G, Livingston PO, Hood C, Gathuru J, Krown SE, Chapman PB, Wolchok JD, Williams LJ, Oldfield RC, Hwu WJ.

Clin Cancer Res. 2003 Nov 1;9(14):5214-20.

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk